Drug
F-18FDG
F-18FDG is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 50.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 1 completed trials
Completion Rate
50%(1/2)
Active Trials
2(50%)
Results Posted
100%(1 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_4
1
25%
Ph not_applicable
1
25%
Ph early_phase_1
1
25%
Ph phase_2
1
25%
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
50.0%
1 of 2 finished
Non-Completion Rate
50.0%
1 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(1)
Terminated(1)
Detailed Status
Completed1
Terminated1
Active, not recruiting1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
50.0%
Most Advanced
Phase 4
Trials by Phase
Early Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 41 (25.0%)
N/A1 (25.0%)
Trials by Status
completed125%
terminated125%
active_not_recruiting125%
recruiting125%
Recent Activity
2 active trials
Showing 4 of 4
completedearly_phase_1
Reliability of the Human Brain Connectome
NCT02193425
active_not_recruitingnot_applicable
Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
NCT04804371
recruitingphase_4
Glucose Consumption in MS Using [F-18]FDG-PET
NCT07087106
terminatedphase_2
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
NCT05009979
Clinical Trials (4)
Showing 4 of 4 trials
NCT02193425Early Phase 1
Reliability of the Human Brain Connectome
NCT04804371Not Applicable
Dual Tracer (68Ga-DOTATATE and 18F-FDG) PET Imaging in G2 & G3 Gastroenteropancreatic Neuroendocrine Tumors
NCT07087106Phase 4
Glucose Consumption in MS Using [F-18]FDG-PET
NCT05009979Phase 2
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4